Serotonin transporter gene deficiency is associated with sudden death of newborn mice through activation of TGF-β1 signalling

Journal of Molecular and Cellular Cardiology

Volumn 47, Issue 5, 2009, Pages 691-697

  Pavone, Luigi Michele ^a   Spina, Anna ^a   Rea, Silviana ^a   Santoro, Dionea ^a   Mastellone, Vincenzo ^b   Lombardi, Pietro ^a   Avallone, Luigi ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

5 HT2A receptor; Cardiac fibrosis; ERK1 2; Mouse model; SERT; SMAD2 3; Sudden neonatal death; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA GALACTOSIDASE; COLLAGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; EMBRYO; GENE EXPRESSION; GENE FUNCTION; HEART ATRIUM SEPTUM; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE; HEART VALVE; HETEROZYGOSITY; HISTOPATHOLOGY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; MOUSE EMBRYO; NEWBORN; NEWBORN DEATH; NONHUMAN; PHENOTYPE; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; SINUS NODE; STAINING; SUDDEN DEATH; SUDDEN INFANT DEATH SYNDROME; TISSUE SECTION; VASCULARIZATION; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; DEATH, SUDDEN; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECEPTOR, SEROTONIN, 5-HT2A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

MUS;

EID: 70349798695     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.07.021     Document Type: Article

References (40)

1. Weese-Mayer D.E., Ackerman M.J., Marazita M.L., and Berry-Kravis E.M. Sudden infant death syndrome: review of implicated genetic factors. Am. J. Med. Genet. A. 143A (2007) 771-788
2. Opdal S.H., and Rognum T.O. The sudden infant death syndrome gene: does it exist?. Pediatrics 114 (2004) e506-e512
3. Paterson D.S., Trachtenberg F.L., Thompson E.G., Belliveau R.A., Beggs A.H., Darnall R., et al. Multiple serotonergic brainstem abnormalities in sudden infant death syndrome. JAMA 296 (2006) 2124-2132
4. Panigrahy A., Filiano J., Sleeper L.A., Mandell F., Valdes-Dapena M., Krous H.F., et al. Decreased serotonergic receptor binding in rhombic lip-derived regions of the medulla oblongata in the sudden infant death syndrome. J. Neuropathol. Exp. Neurol. 59 (2000) 377-384
5. Machaalani R., Say M., and Waters K.A. Serotoninergic receptor 1A in the sudden infant death syndrome brainstem medulla and associations with clinical risk factors. Acta. Neuropathol. 117 (2009) 257-265
6. Kinney H.C., Richerson G.B., Dymecki S.M., Darnall R.A., and Nattie E.E. The brainstem and serotonin in the sudden infant death syndrome. Annu. Rev. Pathol. 4 (2009) 517-550
7. Paterson D.S., Hilaire G., and Weese-Mayer D.E. Medullary serotonin defects and respiratory dysfunction in sudden infant death syndrome. Respir. Physiol. Neurobiol. (2009 May 27) [Electronic publication ahead of print]
8. Dubnov-Raz G., Juurlink D.N., Fogelman R., Merlob P., Ito S., Koren G., et al. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 122 (2008) e710-e715
9. Côté F., Fligny C., Fromes Y., Mallet J., and Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends. Mol. Med. 10 (2004) 232-238
10. Ni W., and Watts S.W. 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol. 33 (2006) 575-583
11. Murphy D.L., Lerner A., Rudnick G., and Lesch K.P. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol. Interv. 4 (2004) 109-123
12. Robiolio P.A., Rigolin V.H., Wilson J.S., Harrison J.K., Sanders L.L., Bashore T.M., et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92 (1995) 790-795
13. Gardin J.M., Schumacher D., Constantine G., Davis K.D., Leung C., and Reid C.L. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 283 (2000) 1703-1709
14. Horvath J., Fross R.D., Kleiner-Fisman G., Lerch R., Stalder H., Liaudat S., et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. 19 (2004) 656-662
15. Rothman R.B., and Baumann M.H. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther. 95 (2002) 73-88
16. Yabanoglu S., Akkiki M., Seguelas M.H., Mialet-Perez J., Parini A., and Pizzinat N. Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors. J. Mol. Cell. Cardiol. 46 (2009) 518-525
17. Khan R., and Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118 (2006) 10-24
18. Massague J., Seoane J., and Wotton D. Smad transcription factors. Genes Dev. 19 (2005) 2783-2810
19. ten DiJike P., and Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 29 (2004) 265-273
20. Zhuang X., Masson J., Gingrich J.A., Rayport S., and Hen R. Targeted gene expression in dopamine and serotonin neurons of the mouse brain. J. Neurosci. Methods 143 (2005) 27-32
21. Soriano P. Generalized lac-Z expression with the ROSA26 Cre reporter strain. Nat. Genet. 21 (1999) 70-71
22. Pavone L.M., Mithbaokar P., Mastellone V., Avallone L., Gaspar P., Maharajan V., et al. Fate map of serotonin transporter-expressing cells in developing mouse heart. Genesis 45 (2007) 689-695
23. Lee J.M., Dedhar S., Kalluri R., and Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell. Biol. 172 (2006) 973-981
24. Bengel D., Murphy D., Andrews A., Wichems C., Feltner D., Heils A., et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol. Pharmacol. 53 (1998) 649-655
25. Fox M.A., Andrews A.M., Wendland J.R., Lesch K.P., Holmes A., and Murphy D.L. A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. Psychopharmacology (Berl) 195 (2007) 147-166
26. Mekontso-Dessap A., Brouri F., Pascal O., Lechat P., Hanoun N., Lanfumey L., et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113 (2006) 81-89
27. Gaspar P., Cases O., and Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 4 (2003) 1002-1012
28. Gustafsson B.I., Tømmerås K., Nordrum I., Loennechen J.P., Brunsvik A., Solligård E., et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111 (2005) 1517-1522
29. Wichman C.L., Moore K.M., Lang T.R., St Sauver J.L., Heise Jr. R.H., and Watson W.J. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo. Clin. Proc. 84 (2009) 23-27
30. Petrov V.V., Fagard R.H., and Lijnen P.J. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 39 (2002) 258-263
31. Dabek J., Kułach A., Monastyrska-Cup B., and Gasior Z. Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'. Pharmacol. Rep. 58 (2006) 799-805
32. Li T., Weng S.G., Leng X.S., Peng J.R., Wei Y.H., Mou D.C., et al. Effects of 5-hydroxytamine and its antagonists on hepatic stellate cells. Hepatobiliary Pancreat. Dis. Int. 5 (2006) 96-100
33. Grewal J.S., Mukhin Y.V., Garnovskaya M.N., Raymond J.R., and Greene E.L. Serotonin 5-HT2A receptor induces TGF-beta1 expression in mesangial cells via ERK: proliferative and fibrotic signals. Am. J. Physiol. 276 (1999) F922-F930
34. Jian B., Xu J., Connolly J., Savani R.C., Narula N., Liang B., et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am. J. Pathol. 161 (2002) 2111-2121
35. Waltenberger J., Lundin L., Oberg K., Wilander E., Miyazono K., Heldin C.H., et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am. J. Pathol. 142 (1993) 71-78
36. Watts S.W. Activation of the mitogen-activated protein kinase pathway via the 5-HT2A receptor. Ann. N. Y. Acad. Sci. 861 (1998) 162-168
37. Garnovskaya M.N., van Biesen T., Hawe B., Casañas Ramos S., Lefkowitz R.J., and Raymond J.R. Ras-dependent activation of fibroblast mitogen-activated protein kinase by 5-HT1A receptor via a G protein beta gamma-subunit-initiated pathway. Biochemistry 35 (1996) 13716-13722
38. Walker G.A., Masters K.S., Shah D.N., Anseth K.S., and Leinwand L.A. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ. Res. 95 (2004) 253-260
39. Schechtman V.L., Harper R.M., Kluge K.A., Wilson A.J., Hoffman H.J., and Southall D.P. Cardiac and respiratory patterns in normal infants and victims of the sudden infant death syndrome. Sleep 11 (1988) 413-424
40. Tester D.J., and Ackerman M. Cardiomyopathic and channelopathic causes of sudden, unexpected death in infants and children. Annu. Rev. Med. 60 (2009) 69-84